On June 22, 2026, China’s National Medical Products Administration (NMPA) approved the world’s first CAR-T cell therapy for solid tumors, marking a historic milestone in cancer treatment and cellular immunotherapy worldwide.
The product, satricabtagene autoleucel injection (brand name: Kyliem, development code: CT041), developed by CARsgen Therapeutics, received approval through the priority review pathway for the treatment of patients with CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have failed at least two prior lines of therapy.
The approval makes Kyliem the first CAR-T cell therapy in the world approved for the treatment of a solid tumor. Until now, commercially approved CAR-T therapies have been limited primarily to hematologic malignancies such as lymphoma and multiple myeloma. The success of CT041 represents a major breakthrough in overcoming the longstanding challenges that have hindered CAR-T therapy in solid tumors, including the immunosuppressive tumor microenvironment and the identification of highly specific tumor targets.
A pioneering innovation from China
Kyliem is an autologous humanized CAR-T cell therapy targeting Claudin18.2 (CLDN18.2), a protein highly expressed in several gastrointestinal cancers. CARsgen Therapeutics began pioneering research into CLDN18.2-targeted CAR-T therapy in 2017 and is widely recognized as one of the first companies globally to identify and validate CLDN18.2 as a promising target for CAR-T treatment in solid tumors.
The approval was supported by the pivotal confirmatory Phase II study CT041-ST-01 (NCT04581473), led by Professor Shen Lin of Peking University Cancer Hospital and conducted across 24 clinical centers throughout China. The study results were published in The Lancet in 2025 and were also presented as an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting.
Clinical trial results demonstrate significant benefit
In a head-to-head comparison against physician’s choice of standard later-line therapies, including nivolumab, paclitaxel, docetaxel, irinotecan, and apatinib, Kyliem demonstrated superiority across key efficacy endpoints.
Key findings included:
- Median progression-free survival (mPFS): 3.25 months versus 1.77 months
- Hazard ratio (HR): 0.37
- Significant improvements in objective response rate (ORR)
- Improved overall survival (OS)
For patients with advanced gastric or gastroesophageal junction cancer who have already failed multiple treatment lines and face limited therapeutic options, a hazard ratio of 0.37 represents one of the most meaningful improvements reported in recent years for later-line treatment settings.
Why this approval matters
Gastric cancer remains a major health challenge worldwide. In China, fewer than 20% of patients are diagnosed at an early stage, and the five-year survival rate for advanced disease remains approximately 10%. Treatment options become increasingly limited after second-line therapy failure.
Kyliem addresses a significant unmet medical need by targeting patients with CLDN18.2-positive and HER2-negative disease, a molecular subtype that represents a substantial proportion of gastric cancer cases but has historically lacked effective targeted treatment options.
Beyond its clinical impact, the approval is widely regarded as a landmark achievement for China’s cell and gene therapy (CGT) industry, demonstrating global leadership in one of the most challenging frontiers of cancer treatment.
Another notable advantage is the treatment experience. Unlike conventional therapies that require repeated administration, CAR-T cells can expand and persist within the patient’s body after infusion. Kyliem is administered as a single intravenous infusion lasting approximately 10 to 20 minutes, potentially providing durable therapeutic benefits without the need for frequent hospital visits.
Looking ahead
While Kyliem is currently approved for advanced gastric and gastroesophageal junction adenocarcinoma, CLDN18.2 is also expressed in several other solid tumors, including pancreatic cancer. CARsgen is actively investigating additional applications for CLDN18.2-targeted CAR-T therapies, raising the possibility of future indications across multiple gastrointestinal malignancies.
The approval of Kyliem represents not only a new treatment option for patients with advanced gastric cancer but also a defining moment in the global development of CAR-T therapy. After years of scientific effort, CAR-T cell therapy has successfully crossed from blood cancers into solid tumors, opening a new chapter in cellular immunotherapy.
